{"id":11859,"date":"2024-02-22T10:47:05","date_gmt":"2024-02-22T10:47:05","guid":{"rendered":"https:\/\/dmsretail.com\/RetailNews\/glp-1-breakthroughs-and-the-impact-on-cpgs\/"},"modified":"2024-02-22T10:47:05","modified_gmt":"2024-02-22T10:47:05","slug":"glp-1-breakthroughs-and-the-impact-on-cpgs","status":"publish","type":"post","link":"https:\/\/dmsretail.com\/RetailNews\/glp-1-breakthroughs-and-the-impact-on-cpgs\/","title":{"rendered":"GLP-1 Breakthroughs and the Impact on CPGs"},"content":{"rendered":"

\"Retail<\/a><\/p>
\n<\/p>\n

\n

Feb 21, 2024<\/p>\n

In
\nepisode 54 of Kantar’s Retail Sound Bites, Barry Thomas, senior
\nretail thought leader, and Rachel Dalton, head of retail insights,
\ndiscuss the rise of GLP-1 weight-loss drugs and the forecasted
\nimplications on the food and beverage industries with Leigh
\nO\u2019Donnell, head of shopper and category insights, and Patricia
\nGregory, global analytics lead, at Kantar.<\/span><\/p>\n

\n
\nHave a topic you’d like us to cover? Contact us
\nat<\/span>\u00a0<\/span>Kantar’s Retail Sound
\nBites Podcast.<\/span><\/span><\/p>\n

Learn
\nmore about GLP-1, other injectable medication usage, and shopper
\nattitudes in our latest study GLP-1 & Injectable
\nMedications.<\/span><\/p>\n


\nBarry’s contact information:

\n
\nbarry.thomas@kantar.com<\/span><\/span>

\n
\nBarry’s LinkedIn<\/span><\/span><\/span><\/p>\n

\n
\nRachel’s contact information:

\nrachel.dalton@kantar.com<\/span>
<\/p>\n

Rachel’s
\nLinkedIn<\/span><\/span><\/span><\/p>\n<\/div>\n